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Over the last two decades, there has been a surge in the number of Cardiac Implantable Electronic Device
(CIED) implantation. These devices improve the quality of life and survival among certain cardiac
patients. However, this beneﬁt might be affected by device complications and one of the most important
ones is CIED infection as it carries signiﬁcant morbidity and mortality. CIED infection can present as a
device pocket infection or endovascular infection and its diagnosis could be challenging. In general,
management of CIED infection involves device removal and antibiotic therapy and requires collaboration
between different clinical teams. Future efforts and research should focus on measures to prevent the
occurrence of this outcome.
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Over the last few decades there has been a signiﬁcant increase
in the number of patients receiving cardiovascular electronic
implantable cardiac devices [1,2]. This was the result of large body
of evidence showing the important role of these devices in
improving both the quality of life and survival among patients
with heart disease [3,4]. In the United States, it is estimated that
about 4.2 million patients underwent implantation of a permanent
pacemaker (PPM) or implantable cardioverter deﬁbrillator (ICD)evier B.V. All rights reserved.
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tion, more CIEDs are implanted in older patients with more
comorbidities [6]. With this growth in number of CIED implanta-
tion has come and increasing recognition of associated complica-
tions. One of these complications is CIED infection, and while its
incidence remains low, the signiﬁcant morbidity and mortality
associated with this complication makes it one of the most serious
complications of CIED implantation [7].2. The magnitude of the problem
There has been a wide range of reported rates of CIED infection
in the literature. The lack of a clear denominator, the inconsistency
in deﬁning CIED infection, and the different follow up durations
used, make the understanding of the true incidence of CIED
infection challenging. In general, it is believed that the risk of
CIED infection after de-novo primary implantation is about 0.5%
and is higher for device replacement or upgrade at around 1–7%
[8–11]. While the incidence rate of CIED infection remains low, the
rate of increase in reported CIED infections each year is alarming
[12,5,13].Fig. 1. CIED pocket infection in a patient who presented 5 weeks after implant.
Fig. 2. CIED endocarditis with bacteremia and TEE showing evidence of vegetations
on the lead across the tricuspid valve.3. Pathophysiology and risk factors
Patient with CIED may get infected at time of initial implanta-
tion or during pocket revision for device change or upgrade [8,2].
Device erosions are by default infected but most commonly are a
secondary manifestation of slow growing underlying infection [8].
Pocket infection can track along the leads leading to endovascular
infection. Less commonly, the pocket or the intravascular portion
of a CIED can become infected as a result of hematogenous seeding
during an episode of bacteremia [8,2,14]. The overlap between
“pocket infection” and “endovascular infection” is large. Many
patients with CIED pocket infection have positive blood cultures
and even vegetation on the leads [7].
Most infections are monomicrobial but about 10% are polymi-
crobial [7]. Staphylococcal species with its ability to form bioﬁlms
account for over 80% of these infections [7,15]. Recently there has
been increasing trend toward methicillin-resistant Staphylococcal
species [7,9,10,15–17]. Poorly timed cultures or prior antibiotic use
can lead to negative cultures despite clear clinical evidence of CIED
infection [7]. Other microorganisms involved include Corynebacter-
ium species, Enterococci, Gram-negative bacilli, fungi, anaerobes,
Candida species, and mycobacteria [7,15].
Different studies have identiﬁed different risk factors for
developing CIED infections. These factors can generally be divided
into three groups: patient-related, procedure-related and micro-
organism related and they are presented in Table 1.Table 1
Risk factors for developing CIED infections.
Patient related Procedure related
Renal dysfunction [28,29] Secondary procedures (device replacement or
as opposed to primary implantation [9,28–31]
Heart failure [28] Presence of temporary pacemaker system at t
implantation [9]
Fever within 24 h prior to implantation
[9]
Presence of more than one lead [31,34]
Diabetes [28] ICD implant as opposed to PPM [10]
Oral anticoagulation use [29] Abdominal implantation [35,36]
Steroid use [34] Early intervention for hematoma or lead dislo
Physician experience [37]4. Diagnosis
Patients with CIED infections can have different presentations.
Most patients present with pulse generator pocket infection
manifested by inﬂammatory changes that involve the pocket itself
(Erythema, tenderness, warmth, drainage, and erosion) [7,15]
(Fig. 1). These local ﬁndings can sometimes be accompanied by
systemic signs and symptoms (fever, chills, nausea/vomiting etc.).
Other patients may present with a device pocket that looks intact,
but with combination of inﬂammatory signs and symptoms
supported by positive blood cultures and imaging data (echocar-
diography or computed tomography) that suggest endovascular
infection of the CIED (Figs. 2 and 3). Patients are classiﬁed as
having CIED endocarditis if they have echocardiographic evidence
of vegetations and two or more positive blood cultures for typical
skin organisms (coagulase-negative Staphylococci, Corynebacter-
ium species, Propionobacterium species, or one positive blood
cultures for all other microorganisms.Microorganism related
upgrade) Bacteremia with Staphylococcal species carries higher risk for




Fig. 3. Surgical view of the same patient in Fig. 2 showing large vegetation
attached to the ventricular lead and the tricuspid valve.
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blood cultures drawn prior to initiation of any antibiotic therapy.
Percutaneous aspiration of the generator pocket should not be
performed as part of the diagnostic evaluation and is considered
contraindicated [2]. Transthoracic echo (TTE) is of great value and if
negative transesophageal echo (TEE) should be performed especially
among patients with positive blood cultures or suspected CIED
endocarditis as it is more sensitive in detecting vegetations. In our
experience, we found that many patients presenting with pocket
infection could have evidence of vegetations on TTE or TEE [7]. This
has lowered our threshold in obtaining TEE for the majority of patients
presenting with CIED infection. One however should be careful in
interpreting echo ﬁndings. It is not unusual to detect echo-densities
adherent to the leads. These often represent thrombus or ﬁbrous
tissue rather than true vegetation. Making the distinction visually
could be challenging and often impossible. Therefore, the interpreta-
tion of the echo ﬁndings should take into account the clinical scenario.
Incidental ﬁnding of a small mass adherent to the leads in the absence
of any ﬁndings to suggest infection is probably thrombus or ﬁbrous
tissue and does not require any intervention. On the other hand, the
lack of echo ﬁndings does not rule out the diagnosis of CIED infection.
In patients with bacteremia without any echocardiographic ﬁndings,
relapsing infections after completion of antibiotic course or persistent
bacteremia despite antibiotic therapy support the diagnosis of CIED
infection that requires its removal [2].
Despite these recommendations, diagnosing CIED infection could
be challenging. Early after implantation procedure it is important to
differentiate CIED pocket infection from incisional erythema or super-
ﬁcial wound infection or stitch abscess. These cases usually resolve
with local measures and sometimes short course of oral antibiotics
directed against staph species. Close follow up is important to avoid
missing the diagnosis of CIED pocket infection. Patients with CIED
pocket infections can present acutely or subacutely after device
implant or replacement procedure, but sometimes it could be months
or even years before the infection becomes manifest [7]. CIED
endocarditis patients can have atypical presentations which could
delay the diagnosis compared to patients with native or prosthetic
valve endocarditis [18].5. Management
The clinical presentation of patients with CIED pocket infection
and those with endovascular infection can vary, but once the
diagnosis is made, the management is similar and involves
removal of all hardware along with antibiotic therapy [2,7,8,15].
Conservative managements with antibiotics therapy only carries
high failure rate and is associated with increased mortality [9].
Removal of the pulse generator and capping the leads should notbe performed as the relapse rate of the retained leads is high [2].
CIED removal could be done percutaneously or surgically. Percu-
taneous extraction has evolved signiﬁcantly over the years and
currently is the method of choice for CIED removal. These
procedures are usually safe but could be associated with signiﬁ-
cant risks including vascular or cardiac perforation leading to
major bleeding or tamponade, hemothorax, pulmonary embolism
and death [7]. Therefore they should be performed in centers that
can provide the clinical skills, expertise, the appropriate equip-
ment, and readily available surgical back up in case of complica-
tions. Surgical extraction is usually reserved for patients who
already failed percutaneous extraction, or with retained leads
not amenable to percutaneous extraction, patients with evidence
of valve involvement with endocarditis that requires surgical
intervention, presence of infected epicardial leads, or evidence of
large vegetations over 2 cm in size. Recent data suggest that
percutaneous extraction could be done safely even in the presence
of vegetations larger than 2 cm, however, these cases should be
evaluated individually on a case-by-case basis. Many factors other
than the vegetation size play a role in the decision-making process
including the general condition of the patient, comorbidities,
involvement of the tricuspid valve, and the need and timing for
reimplanting the CIED. For example, the patient who is
pacemaker-dependent with evidence of endovascular infection
and intracardiac vegetations represent a clinical dilemma as there
will not be a period of “hardware free” to allow the infection to
resolve prior to reimplant. These patients could be managed
surgically with CIED removal and debridement of the valve and
temporary epicardial lead placement to provide pacing followed
by endovascular reimplant of a new device, or they can undergo
percutaneous removal of CIED and implantation of endovascular
temporary pacing lead, followed by surgical implantation of
permanent epicardial leads. Extraction strategy should always
take into account reimplant strategy and often requires team
approach that includes the electrophysiologist, the infectious
disease specialist, and the surgeon. While surgical approach could
be successful in removing the leads, often times this could not be
accomplished due to extensive ﬁbrosis. Cutting both sides of the
lead and leaving a remnant of an infected lead should be avoided.
These remnants could cause recurrent infection and their extrac-
tion can represent a major technical challenge. Therefore these
cases require collaboration. If the leads are cut distally at time of
surgery, it is important to maintain the proximal portion of the
lead in order to perform percutaneous removal of the remnant.
Patients with Biventricular pacemakers or deﬁbrillators represent
an added challenge when they develop an infection. Upon the
removal of the infected device, their hemodynamics can be
affected negatively and therefore the operator should anticipate
these negative hemodynamic effects and be ready to manage
them. These patients require close observation sometimes in
intensive care units and often require hemodynamic support
medically or using intra-aortic balloon pumps if needed. Whether
performed percutaneously or surgically, complete removal of all
hardware is critical to effectively treat the infection. Complete
removal and debridement of the ﬁbrous scar and necrotic tissue in
the device pocket should be performed with minimal disruption of
the healthy fat, skin or muscle tissue. Samples of the pocket tissue
and lead tips should be sent for gram stain and cultures.
Antimicrobial therapy plays an important role in the manage-
ment of patients with CIED infections. After appropriate cultures
are sent, antibiotics could be started. Since the majority of
infections are due to staphylococcal species and signiﬁcant portion
of these are methicillin resistant, we usually use vancomycin as an
initial empiric therapy and then we adjust the therapy based on
the culture data. Empiric Gram negative coverage is usually
reserved for ill patients in whom delaying therapy could be
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is removed and cultures are sent form the device pocket and the
lead in cases of infection limited to the pocket or device erosion in
the absence of any other systemic signs or symptoms or infection.
The data about the duration of antibiotic therapy are limited but in
general, patients with CIED pocket infection are treated for 2 weeks
and patients with endovascular infection are usually treated for
4–6 weeks.6. Reimplant
The management plan for treating CIED infection should take
into consideration the need for reimplant as this might affect our
approach in CIED removal as discussed earlier. Reimplant should
not be an automatic decision, but rather CIED removal should be
an opportunity to reassess the need for the device. In our
experience, almost one third of the patients undergoing CIED
removal for infection did not require immediate reimplant [7].
Patients who had an ICD implanted for primary prevention for
impaired left ventricular function might not need it if they have
never had ICD therapies and the ventricular function has now
recovered with medical therapy. Patients who underwent pace-
maker implant for possible sinus node dysfunction might not need
it (at least not immediately) if the data from the prior device
showed minimal need for pacing. The emergence of new and
advanced medical conditions that would affect survival or quality
of life like would make us avoid reimplanting an ICD for primary
prevention.
When reimplant is needed, it should be performed on the
opposite side of the chest. Other alternative approaches include
abdominal device with transiliac lead implantation or epicardial
lead surgical implantation. There are no randomized trials to guide
the timing of reimplant, but this usually depends on several factors
including the type of infection, the presence of positive blood
cultures, and the pathogen involved. Patients with positive blood
cultures and no evidence of endocarditis (no valve vegetation) can
be reimplanted if the repeat blood cultures after CIED removal
remain negative for 72 h.
Patients with CIED endocarditis should not be reimplanted
until at least 14 days after the ﬁrst negative blood cultures after
CIED removal. This is feasible in patients who are not dependent
on the device. Wearable external deﬁbrillator can provide patients
with time to recover before a new ICD is reimplanted especially for
patients who had ICD implanted for primary prevention and have
no pacing indication. For patients who are pacemaker dependent,
surgical epicardial pacemaker system implantation provides an
alternative approach.7. Outcomes and economic burden
CIED infections carry signiﬁcant morbidity and mortality [7,15].
In-hospital mortality among patients admitted with CIED infection
ranges between 4% and 10% [7,10,17–19] and 1-year mortality
ranges between 15% and 20% [7,17,18,20]. Mortality is higher among
patients with endovascular infection (especially with endocarditis)
compared to patients with pocket infection [7,18]. Contrary to
common belief, only a small proportion of the in-hospital mortality
is directly related to the extraction procedure itself, [7] reﬂecting
the serious signiﬁcance of CIED infection itself and the comorbid-
ities among these patients.
The high morbidity and mortality, along with prolonged
hospital stay, antimicrobial therapy, added to the cost of extraction
and potential reimplantation of a new device, all result insigniﬁcant ﬁnancial burden that has been increasing over the last
two decades [5,21,22].8. Prevention
The best strategy to address CIED infection is to prevent its
occurrence. This process starts with the decision of implanting
a CIED. Thorough evaluation of the recipient of the device
is invaluable and the following questions should always be
addressed. Is the device indicated? Is the timing appropriate?
Is the patient ready? CIED should not be implanted if there is any
documented fever or concern for an active infection. Temporary
pacemaker should be avoided if possible prior to implanting a new
device. Patients who are found to be colonized with methicillin
resistant Staphylococcus aureus can beneﬁt from decolonization
using nasal application of Bactroban ointment [23]. All efforts
should be made to minimize the risk of bleeding and hematoma
including holding the use of anticoagulants if possible. In our
experience, if anticoagulation cannot be interrupted, we ﬁnd that
performing the implantation on coumadin (with INR equal or less
than 2.5) carries less risk of hematoma than bridging with heparin.
Recommendations for CIED implantation while using newer oral
anticoagulants require further studies. The use of low molecular
weight heparin should be avoided around the time of implanta-
tion. Strict surgical techniques should be applied at time of
implantation, these include antiseptic skin preparation, washing
the pocket with saline or antibiotic solution and perioperative
antibiotic use [24–26]. Many centers use ﬁrst generation cepha-
losporin, however, the increasing proportion of methicillin resis-
tance among Staph species have led many centers, including our
own institution, to use vancomycin for perioperative prophylaxis
[2,7]. Future advancement in minimizing CIED infection include
the use or antibacterial envelope [27]. Rechargeable batteries in
the future would hopefully minimize the need for CIED change
procedures which carry a high risk for infection.9. Conclusions
CIED infections represent a major complication after CIED and
carries signiﬁcant mortality and morbidity. Management of this
complication usually involves device and lead removal along with
antibiotic therapy. Future advancement should focus on measures
to prevent CIED infections.10. Disclosures
KGT: none.
BLW: medical advisory boards for Medtronic, St Jude Medical
and Spectranetics.
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